Clinical trials: Neurological Disease
Corneal Scar
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days.
- Trial name
- NCT06257355
- Testing
- CSB-001 Ophthalmic Solution 0.1%
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Claris Biotherapeutics, Inc.
Amyotrophic Lateral Sclerosis
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
- Trial name
- ADOREXT (NCT05866926)
- Testing
- FAB122
- Where
- Spain
- Volunteers
- 201 people
- Sponsor
- Ferrer Internacional S.A.
Relapsing-remitting Multiple Sclerosis
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod.
- Trial name
- NCT02720107
- Testing
- fingolimod
- Where
- 26 sites in Germany
- Volunteers
- 133 people
- Sponsor
- Novartis Pharmaceuticals
Brain Tumour, High Grade Glioma
SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue
The objective of this clinical investigation is to assess the safety and performance of the SonoClear Acoustic Coupling Fluid (ACF).
- Conditions
- Brain Tumour, High Grade Glioma, Low-grade Glioma, Glioblastoma
- Trial name
- NCT04734444
- Testing
- SonoClear ACF
- Where
- 4 sites in Germany, Italy and 1 more
- Volunteers
- 45 people
- Sponsor
- SonoClear AS
Stroke
Cytoflavin in the Complex Rehabilitation of Stroke Patients
It is known that the acute period of stroke occurs is accompanied by oxidative stress, when intense generation of reactive oxygen species (ROS) have a toxic effect, which causes oxidative degradation of proteins, lipids, nucleic…
- Trial name
- NCT05935787
- Testing
- Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
- Where
- 3 sites in Russia
- Volunteers
- 240 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Cancer, Chronic Pain
Tapentadol in Chronic Malignant Tumour Related Pain
The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain.
- Conditions
- Cancer, Chronic Pain, Pain
- Trial name
- NCT01264887
- Testing
- Tapentadol Prolonged Release
- Where
- 12 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 31 people
- Sponsor
- Grünenthal GmbH
Epilepsy Intractable
A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy
To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy.
- Trial name
- NCT02987114
- Testing
- PLT101
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- PhytoTech Therapeutics, Ltd.
Tuberous Sclerosis Complex
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be…
- Trial name
- NCT02962414
- Testing
- everolimus
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Fibromyalgia
A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia
The purpose of this study is to confirm the efficacy and safety of duloxetine 60-120 mg once daily in comparison to placebo on symptom improvement in patients meeting criteria for fibromyalgia aged 18 and older.
- Trial name
- NCT00673452
- Testing
- duloxetine hydrochloride
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
The study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.
- Trial name
- OleroMAX (NCT06675955)
- Testing
- Ocrelizumab
- Where
- 56 sites in Bulgaria, France and 4 more
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Chronic Pain, Spasticity, Muscle
Medtronic PSR TDD PMCF
The purpose of this study is to provide continuing evaluation and reporting of safety and performance of the SynchroMed II Infusion System within its intended use. Data will support post-market surveillance obligations.
- Trial name
- NCT04714385
- Where
- 15 sites in Belgium, Czechia and 6 more
- Volunteers
- 209 people
- Sponsor
- Medtronic
Restless Legs Syndrome
Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
The objective of this study is to evaluate the efficacy and safety of ASP8825 (gabapentin enacarbil) for long-term treatment of restless legs syndrome patients.
- Trial name
- NCT02658188
- Testing
- ASP8825
- Where
- 10 sites in Japan
- Volunteers
- 182 people
- Sponsor
- Astellas Pharma Inc
Duchenne Muscular Dystrophy
Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy
In some patients with Duchenne muscular dystrophy (DMD), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the dystrophin protein.
- Trial name
- NCT00264888
- Testing
- PTC124
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- PTC Therapeutics
Alzheimer's Disease
Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation
The purpose of this study is to find a modified release oral tablet formulation for this drug, which will be safe and well tolerated.
- Trial name
- NCT02710188
- Testing
- HTL0009936 modified release, HTL0009936 immediate release
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Parkinson s Disease
Comparison of Immersive and Non-Immersive Virtual Reality Rehabilitation in Parkinson's Disease
Parkinson's disease commonly affects walking ability, balance, mobility, and cognitive function, increasing the risk of falls and reducing independence.
- Trial name
- VR-PD (NCT07659288)
- Testing
- Immersive Virtual Reality, Non-Immersive Virtual Reality
- Where
- Chile
- Volunteers
- 16 people
- Sponsor
- Neuro Group XR Inc.
Progressive Multiple Sclerosis
ABA-101 in Participants With Progressive Multiple Sclerosis
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans.
- Trial name
- NCT06566261
- Testing
- ABA-101
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Abata Therapeutics
Hearing Loss
Clinical Investigation and Validation of a Self-fitted Air-conduction Hearing Aid
Approximately 48 million people in the United States have hearing loss or hearing difficulties in noisy environments. Concha Inc.
- Trial name
- NCT06167161
- Testing
- Hearing aid
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Concha Inc.
Angina Pectoris
Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients
The purpose of this study is to evaluate the effects of Succinate Metoprolol(Betaloc ZOK®) (95 - 190 mg) on heart rate in the Stable angina patients.
- Trial name
- NCT01213173
- Testing
- Succinate Metoprolol (Betaloc ZOK®)
- Where
- 10 sites in China
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
Muscle Spasticity
BOTOX® Economic Spasticity Trial (BEST)
This is a study to investigate if patients who have had a stroke and suffer from spasticity might benefit from being given BOTOX® in addition to the normal Standard Care.
- Trial name
- NCT00549783
- Testing
- Botulinum Toxin Type A 900kD
- Where
- 4 sites in Canada, Germany and 2 more
- Volunteers
- 274 people
- Sponsor
- Allergan
Mixed Hearing Loss
Long Term Results With the Vibrant Soundbridge in Patients With Mixed Hearing Loss: a 60-month Longitudinal Study
Vibrant Soundbridge (VSB, MED-EL, Innsbruck) Active middle ear implants (AMEI) can benefit patients who are unable to use conventional hearing aids (HA) due to medical reasons, discomfort or unsuccessful rehabilitation.
- Trial name
- NCT05793580
- Testing
- Vibrant Soundbridge active middle ear implant
- Where
- France
- Volunteers
- 31 people
- Sponsor
- MED-EL Elektromedizinische Geräte GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.